PREDUCTAL MV: EFFECT ON EFFICIENCY OF THERAPY AND QUALITY OF LIFE IN PATIENTS WITH VENTRICULAR ARRHYTHMIAS AND METABOLIC SYMDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The impact of intake of the myocardial metabolic cytoprotector trimetazidine (Preductal MB) on the efficiency of antiarrhythmic, antianginal therapy and quality of life was evaluated in patients with ventricular arrhythmias (VA), coronary heart disease (CHD), and metabolic syndrome (MS). The investigation enrolled 36 patients with VA and MS who received antiarrhythmic and MS therapies; half of the randomized was additionally given trimetazidine (Preductal MB). According to the data of the investigation, MS therapy using trimetazidine (Preductal MB) in patients with VA and CHD results in a significant improvement in quality of life and exercise tolerance and in higher efficiency of antiarrhythmic and antianginal therapy.

Full Text

Restricted Access

About the authors

R. Zhizhov

Kirov State Medical Academy

Email: doc1005@mail.ru

O. Solovyev

Kirov City Clinical Hospital № 1

Email: doc1005@mail.ru
Professor MD

S. Kononov

Kirov City Clinical Hospital № 1

Email: doc1005@mail.ru
Candidate of Medical Sciences

E. Onuchina

Kirov State Medical Academy

Email: doc1005@mail.ru
Candidate of Medical Sciences

E. Pavlov

Kirov State Medical Academy

Email: doc1005@mail.ru
Candidate of Medical Sciences

References

  1. Кушаковский М.С. Аритмии сердца / СПб: Фолиант, 1998; с. 206.
  2. Mortality rates after 10,5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. The Multiple Risk Factor Intervention Trial Research Group // JAMA. - 1990; 263: 1795-801.
  3. Cardiovascular risk factors. Insights from Framingham Heart Study. O'Donnell C.J., Elosua R. // Rev Esp Cardiol. - 2008 Mar; 61 (3): 299-310.
  4. Hubert H.B., Feinleib M., McNamara P.M. et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study // Circulation. - 1983; 67: 968-77.
  5. ВНОК. Национальные клинические рекомендации. М., 2010. Шестакова М.В., Брескина О.Ю. Инсулинорезистентность: патофизиология, клинические проявления, подходы к лечению // Consilium Medicum. -2002; 10 (4): 523-7.
  6. Lakka H., Laaksonen D., Lakka T. et al.The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men // JAMA. - 2002; 288: 2709-16.
  7. Kantor P., Lucien A., Kozak R. et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase // Circ. Res. -2000; 86: 580-8.
  8. Gottlieb S. Dead is dead: artificial definitions are no substitute // Lancet. -1997; 349: 662-5.
  9. Pratt C., Greenway P., Schoenfield M. et al. Exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials // Circulation. - 1996; 93: 519-24.
  10. Cairns J., Connolly S., Gent M. et al. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study // Circulation. - 1991; 84: 550
  11. Ostgren C., Merlo J., Rastam L. et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community // Diabetes Obes. Metab. - 2004; 6 (5): 367-74.
  12. Paulson D. The diabetic heart is more sensitive to ischemic injury // Cardiovasc. Res. - 1997; 34: 104-12.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies